Safety of lamivudine treatment for chronic hepatitis B in early pregnancy

Table 1 Clinical information of mothers who took lamivudine treatment before or during early pregnancy n (%)

	Treated population (n = 92)
Average age (yr)	30.5 ± 3.1
Primipara	88 (95.7)
Cirrhosis	2 (2.2)
HBeAg positivity rate	74 (80.4)
HBV DNA > 105 copies/mL in early pregnancy	16 (17.4)
Treatment before pregnancy
Naive	15 (16.3)
LAM	41 (44.6)
ADV	28 (30.4)
LAM→ADV	3 (3.3)
ETV	2 (2.2)
ETV→ADV	1 (1.1)
IFN + LdT	2 (2.2)

LAM: Lamivudine; ADV: Adefovir dipivoxil; ETV: Entecavir; LdT: Telbivudine; IFN: Interferon; HBeAg: Hepatitis B e antigen.

Table 2 Adverse events and laboratory abnormalities during pregnancy and the perinatal period (n = 72) (%)

	Adverse events	Cases
Pregnancy	Vaginitis	12 (16.7)
	Gestational diabetes	6 (8.3)
	Arrhythmia/abnormal ECG	4 (5.6)
	Nausea and vomiting	3 (4.2)
	Common cold	3 (4.2)
	Oligohydramnios	3 (4.2)
	Polyhydramnios	2 (2.8)
	Greater than moderate anemia (Hb < 9 g/L)	2 (2.8)
	Placenta previa	2 (2.8)
	Inguinal hernia	1 (1.4)
	Hypothyroidism	1 (1.4)
	ALT ≥ 2 × ULN	16 (22.2)
	HBV DNA breakthrough	6 (8.3)
	Elevated total bilirubin	2 (2.8)
	Thrombocytopenia	2 (2.8)
	Elevated CK (1-2 degrees)	1 (1.4)
Perinatal period	Premature rupture of the membranes	8 (11.1)
	Preterm	5 (6.9)
	Meconium staining of the amniotic fluid 2-3 degrees	4 (5.6)
	Antepartum hemorrhage	3 (4.2)
	Placenta accreta	1 (1.4)

ECG: Electrocardiogram; Hb: Hemoglobin; ALT: Alanine aminotransferase; ULN: Upper limit of normal; HBV: Hepatitis B virus; CK: Creatine kinase.